Recent advancements in oncology have significantly improved the range of available treatment options for cancer patients in India. However, the financial burden associated with long-term care, including surgery, radiation, and newer targeted therapies or immunotherapy, often forces patients to discontinue life-saving treatment prematurely. For many families, the exorbitant cost of medicine remains the primary barrier to completing a full medical regimen.
To address these financial strains, the National Pharmaceutical Pricing Authority (NPPA) recently announced a decision to cap trade margins at 30% of the price to retailers for 137 identified non-scheduled anti-cancer medications. Set to take effect on November 9, the move is projected to generate annual savings of approximately ₹2,500 crore for patients nationwide. Depending on the brand and formulation, officials expect the retail prices of certain drugs to decline by as much as 70%.
The policy change is particularly notable for its inclusion of newer cancer treatments, which are often the most expensive components of a care plan. However, both patient advocates and medical professionals have tempered expectations, noting that trade margin controls address only one facet of a systemic issue. Concerns remain regarding high prices set at the manufacturing level, the limited availability of lower-cost generic alternatives, and the cumulative expenses of hospital stays and clinical procedures that extend well beyond the cost of medication alone.
The urgency of the situation was underscored by recent correspondence from Karnataka’s Health Minister, U.T. Khader, to Union Health Minister J.P. Nadda. Following an investigation by the state’s Food Safety and Drug Administration, Karnataka flagged critical discrepancies between the landing costs—the price at which hospitals procure drugs—and the maximum retail price (MRP) charged to patients. In some documented instances, the markup ranged from 10 to over 52 times the actual procurement cost.
Specific examples brought to the Centre’s attention included the drug Gufipol, which had a landing cost of ₹86 but an MRP of ₹4,528. Similar disparities were noted in other essential medications such as Taxocare 120 mg, which jumped from a landing cost of ₹1,000 to an MRP of ₹21,617. Another example, Bevatas 400 mg, showed a procurement cost of ₹5,850 against a retail price of ₹62,690. These figures illustrate the immense pressure on households, many of whom are already navigating modest incomes.
The human toll of these pricing gaps is evident in clinical settings like the Kidwai Memorial Institute of Oncology in Bengaluru. Patients, particularly those traveling from tier-two and tier-three towns, often face impossible choices when their funds are exhausted mid-treatment. For a garment factory worker with stage IV-A cancer, the cost of medicines alone—estimated at ₹93,000—already exceeds the reach of a modest monthly household income of ₹28,000.
Similarly, for patients requiring advanced interventions such as immunotherapy, costs can quickly climb to between ₹2.4 lakh and ₹8 lakh over a few months. For those in such circumstances, even with capped trade margins, the remaining financial gaps continue to pose a significant risk of treatment abandonment. As stakeholders continue to evaluate the impact of the NPPA’s order, the consensus among experts is that true financial protection for cancer patients will require a multifaceted approach that addresses both procurement transparency and the affordability of innovative medical technologies.
Comments